Condition 1: COVID-19 pneumonia. Condition 2: Acute liver injury. Pneumonia due to SARS-associated coronavirus Acute and subacute hepatic failure
Conditions
Interventions
Intervention 1: Intervention group: including 44 patients who will receive 1000 mg of acetylcysteine intravenously every 12 hours for 5 days. Intervention 2: Control group: including 44 patients who w
Sponsors
Artesh University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosed positive for Covid-19 based on PCR testing Admitted in intensive care unit Treated with remdesivir
Exclusion criteria
Exclusion criteria: Positive history of any underlying liver disease e.g. fatty liver, or acute or chronic hepaptitis Plasma levels of liver transaminases over 100 IU/L on the first day of ICU admission Simultaneous use of any hepatotoxic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The prevention of acute liver injury. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement of serum levels of liver aminotransferases. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total bilirubin serum levels. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement.;Prothrombin time. Timepoint: Days 1, 2, 3, 4 and 5 of trial. Method of measurement: Laboratory measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Hazrati
Artesh University of Medical Sciences
Outcome results
None listed